Why the study?
The USPSTF commissioned an evidence review on the benefits and harms of statins to reduce CVD-related morbidity, mortality, or all-cause mortality to update its 2016 recommendation.
Does statin use reduce CVD-related morbidity or mortality or all-cause mortality in adults 40 years or older without a history of known CVD?
Does statin use reduce CVD-related morbidity or mortality or all-cause mortality in adults 40 years or older without a history of known CVD?
The USPSTF recommends statin therapy for primary prevention of CVD in adults aged 40 to 75 years with at least one CVD risk factor and an estimated 10-year CVD risk of 10% or greater.
No takes yet. Share an insight, caveat, or question.
Supports statin initiation for primary prevention in eligible adults; reinforces USPSTF guideline recommendations.
Mangione et al. (2022) conducted a review in Cardiovascular disease. Statin was evaluated on CVD-related morbidity or mortality or all-cause mortality. Statin use for the primary prevention of CVD in adults aged 40 to 75 years with ≥1 CVD risk factor and a 10-year CVD risk of ≥10% provides at least a moderate net benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: